Functional constipation (FC) is a common condition in childhood, with an estimated prevalence of 0.7% to 29%.The diagnosis and treatment of FC can be difficult tasks, and children are often referred to specialist services causing treatment to become expensive and time-consuming.The standard treatment based on osmotic laxatives (mainly PEG). The recovery rate is 50% to 60% after 1 year of treatment, with 50% of the children having relapse within 5 years. Studies in adults have established the effectiveness of some lactic acid bacteria in the treatment of chronic constipation.
Functional constipation (FC) is a common condition in childhood, with an estimated prevalence of 0.7% to 29%.The diagnosis and treatment of FC can be difficult tasks, and children are often referred to specialist services causing treatment to become expensive and time-consuming.The standard treatment based on osmotic laxatives (mainly PEG). The recovery rate is 50% to 60% after 1 year of treatment, with 50% of the children having relapse within 5 years. Studies in adults have established the effectiveness of some lactic acid bacteria in the treatment of chronic constipation.However, it is unclear whether similar effects occur in children. Lactobacilli and Bifidobacteria are the most studied species showing a high safety profile. Both are able to promote colonic peristalsis which could be beneficial for the treatment of constipation .Even though traditional treatment is well established and safe, high proportion of children need prolonged treatment for several months or even years. For many parents there is a concern regarding prolonged treatment with PEG .Lactobacilli, bifidobacteria and FOS (fructooligosaccharide) increase stool frequency and decrease consistency in healthy adults and therefore could prevent recurrence of constipation after PEG withdrawal .The principle investigator hypothesize that treatment with probiotics adjunct to PEG and several months thereafter could decrease the proportion of children needed permanent or prolonged treatment (\>12 months) with PEG. The importance of the study and its practical benefits: Treatment with PEG for FC is well established and is considered safe. Despite that, a high proportion of children need prolonged treatment for several months or even years. For many parents there is a concern regarding prolonged treatment with PEG. Previous studies did not demonstrate efficacy of treatment with probiotics or prebiotics in FC. Neither of these studies assessed effectiveness probiotics/prebiotic products as adjunct to the traditional treatment (PEG) of FC in shortening its period. A recently published studies including from Israel, demonstrated efficacy of Lactobacillus reuteri in irritable bowel syndrome, infantile colic and functional abdominal pain .Therefore, demonstration of positive effect of treatment with probiotic product in FC, could imply for potential use of this product in other functional gastrointestinal disorders among children.
The treated arm will receive 5 drops per day for 48 weeks
The control arm will receive 5 drops per day for 48 weeks
Emek medical center
Afula, Israel
The prevalence of constipation recurrence
according to Rome IV criteria
Time frame: This measure will be assessed at weeks 24.
The prevalence of constipation recurrence
according to Rome IV criteria
Time frame: This measure will be assessed at weeks 60.
failure of maintaining normal bowel movements without PEG and the need to resume PEG treatment
according to Rome IV criteria
Time frame: This measure will be assessed at weeks 24.
failure of maintaining normal bowel movements without PEG and the need to resume PEG treatment
according to Rome IV criteria
Time frame: This measure will be assessed at weeks 60.
The number of bowel movements per week
The investigator will collect the information during the following visits from the patient
Time frame: This measure will be assessed at baseline and at 24, 36, 48 and 60 weeks after enrolment
The number of episodes of fecal incontinence per week
The investigator will collect the information during the following visits from the patient
Time frame: This measure will be assessed at baseline and at 24, 36, 48 and 60 weeks after enrolment
The stool consistency in patients without PEG treatment
The investigator will collect the information during the following visits from the patient
Time frame: This measure will be assessed at baseline and at 24, 36, 48 and 60 weeks after enrolment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
50